Sugi Predict

Sugi Predict / Compounds / SCHEMBL14719082

SCHEMBL14719082

SCHEMBL14719082

Cc1cnc(Cl)nc1-c1cn(C)c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK5 Q00535 3/20 0.52
▸ CDK5R1 Q15078 2/20 0.52
▸ USP2 O75604 6/20 0.44
▸ CYP1A2 P05177 6/20 0.44
▸ MEN1 O00255 5/20 0.44
▸ CYP3A4 P08684 5/20 0.44
▸ KMT2A Q03164 5/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ CASP1 P29466 4/20 0.43
▸ CASP7 P55210 4/20 0.43
▸ TSHR P16473 2/20 0.43
▸ HBB P68871 1/20 0.43
▸ LMNA P02545 3/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ PRKD3 O94806 1/20 0.43
▸ PRKD1 Q15139 1/20 0.43
▸ PRKD2 Q9BZL6 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30052020 1.00 CDK5 (0.52) CDK5CDK5R1USP2CYP1A2MEN1
SCHEMBL517423 0.87 CDK5 (0.53) CDK5CDK5R1USP2CYP1A2MEN1
SCHEMBL29994241 0.87 CDK5 (0.53) CDK5CDK5R1USP2CYP1A2MEN1
SCHEMBL17373164 0.85 CDK5 (0.57) CDK5CDK5R1USP2CYP1A2MEN1
SCHEMBL518274 0.85 CDK5 (0.51) CDK5CDK5R1USP2CYP1A2MEN1
SCHEMBL30337550 0.85 CDK5 (0.51) CDK5CDK5R1USP2CYP1A2MEN1
SCHEMBL30337215 0.84 CDK5 (0.50) CDK5CDK5R1USP2CYP1A2MEN1
SCHEMBL28987633 0.84 CDK5 (0.50) CDK5CDK5R1USP2CYP1A2MEN1
SCHEMBL29974859 0.83 CDK5 (0.74) CDK5CDK5R1USP2CYP1A2MEN1
SCHEMBL25497122 0.83 CDK5 (0.49) CDK5CDK5R1USP2CYP1A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425476-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2024-12-26 — — US disclosed
US-20240182441-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2024-06-06 — — US disclosed
WO-2024022244-A1 HETEROCYCLIC COMPOUND HAVING BIOLOGICAL ACTIVITY 首药控股(北京)股份有限公司 2024-02-01 — — WO disclosed
CN-111892579-B Kinase inhibitors 上海艾力斯医药科技股份有限公司 2023-07-25 — — CN disclosed
CN-111875585-B Kinase inhibitors 上海艾力斯医药科技股份有限公司 2023-06-23 — — CN disclosed
CN-115974845-A Preparation method of oxitinib intermediate 奥锐特药业股份有限公司 2023-04-18 — — CN disclosed
US-20230115945-A1 AMINOPYRIMIDINE COMPOUNDS TYRA BIOSCIENCES, INC. 2023-04-13 — — US disclosed
EP-4119551-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS Astrazeneca AB (SE) 2023-01-18 — — EP disclosed
US-11524951-B2 2-(2,4,5-substituted-anilino)pyrimidine compounds ASTRAZENECA AB (SE) 2022-12-13 — — US disclosed
EP-4086246-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS AS EGFR MODULATORS AstraZeneca AB (SE) 2022-11-09 — — EP disclosed
US-20180162832-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2018-06-14 — — US disclosed
EP-3333161-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER Astrazeneca AB (SE) 2018-06-13 — — EP disclosed
EP-3009431-B1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER ASTRAZENECA AB (SE) 2017-10-25 — — EP disclosed
US-20170253594-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-07 — — US disclosed
US-9732058-B2 2-(2,4,5-substituted-anilino)pyrimidine compounds ASTRAZENECA AB (SE) 2017-08-15 — — US disclosed
EP-3009431-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER Astrazeneca AB (SE) 2016-04-20 — — EP disclosed
EP-2736895-B1 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER ASTRAZENECA AB (SE) 2016-01-06 — — EP disclosed
US-20150119379-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2015-04-30 — — US disclosed
US-8946235-B2 2-(2,4,5-substituted-anilino) pyrimidine compounds ASTRAZENECA AB (SE) 2015-02-03 — — US disclosed
US-20130053409-A1 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2013-02-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053409-A1 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS EGFR, ERBB2, ERBB3 CDK5 550/4885CDK5R1 358/4885USP2 4590/4885
US-20180162832-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS EGFR, ERBB2, ERBB3 CDK5 550/4885CDK5R1 358/4885USP2 4590/4885
US-20230115945-A1 AMINOPYRIMIDINE COMPOUNDS FGFR2, FGFR1, FGFR4 CDK5 72/4885CDK5R1 120/4885USP2 4035/4885
US-20240425476-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS EGFR, ERBB2, ERBB3 CDK5 550/4885CDK5R1 358/4885USP2 4590/4885
US-20150119379-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS EGFR, ERBB2, ERBB3 CDK5 550/4885CDK5R1 358/4885USP2 4590/4885
US-11524951-B2 2-(2,4,5-substituted-anilino)pyrimidine compounds EGFR, ERBB2, ERBB3 CDK5 550/4885CDK5R1 358/4885USP2 4590/4885
US-20170253594-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION ERBB2, EGFR, ERBB3 CDK5 258/4885CDK5R1 442/4885USP2 2742/4885
US-20240182441-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS EGFR, ERBB2, ERBB3 CDK5 550/4885CDK5R1 358/4885USP2 4590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.